Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial
暂无分享,去创建一个
J. Václavík | M. Plachy | T. Václavík | M. Táborský | R. Sedlák | Jirí Jarkovský | E. Kociánová | Karel Navrátil | J. Plášek | Roman Husár
[1] R. Carey. Resistant hypertension. , 2013, Hypertension.
[2] J. Václavík,et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol. , 2011, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[3] B. Álvarez-Álvarez,et al. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin–angiotensin–aldosterone system , 2010, Journal of hypertension.
[4] Josh Batterink,et al. Spironolactone for hypertension. , 2010, The Cochrane database of systematic reviews.
[5] J. Connell,et al. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO , 2010, Journal of hypertension.
[6] E. Muxfeldt,et al. Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension , 2010, Hypertension.
[7] G. Bakris,et al. Original Report: Patient-oriented, Translational Research Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade Nephrology American Journal Of , 2022 .
[8] B. Imholz,et al. Aldosterone-receptor antagonism in hypertension , 2009, Journal of hypertension.
[9] W. Elliott. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research , 2009 .
[10] W. Young,et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. , 2008, The Journal of clinical endocrinology and metabolism.
[11] W. Elliott. Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension , 2008 .
[12] F. Zannad. Aldosterone antagonist therapy in resistant hypertension , 2007, Journal of hypertension.
[13] D. Lane,et al. Low-dose spironolactone in the management of resistant hypertension: a surveillance study , 2007, Journal of hypertension.
[14] N. Chapman,et al. Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension , 2007, Hypertension.
[15] Y. Sharabi,et al. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. , 2006, American journal of hypertension.
[16] W. Ambrosius,et al. Improvement in Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension , 2005, Hypertension.
[17] Yutaka Imai,et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. , 2005, Journal of hypertension.
[18] Azra Mahmud,et al. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. , 2005, American journal of hypertension.
[19] G. London. Role of arterial wall properties in the pathogenesis of systolic hypertension. , 2005, American journal of hypertension.
[20] D. Calhoun,et al. Efficacy of low-dose spironolactone in subjects with resistant hypertension. , 2003, American journal of hypertension.
[21] Peter Sleight,et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. , 2003, JAMA.
[22] B. Davis,et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). , 2002, Journal of clinical hypertension.
[23] A. Lincoff,et al. The role of spironolactone in the treatment of patients with refractory hypertension. , 2001, American journal of hypertension.
[24] G Parati,et al. Blood pressure measuring devices: recommendations of the European Society of Hypertension , 2001, BMJ : British Medical Journal.
[25] R H Fagard,et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. , 1999, Archives of internal medicine.
[26] D. Levy,et al. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. , 1999, Circulation.
[27] E. Bravo,et al. Medical Management of Aldosterone-Producing Adenomas , 1999, Annals of Internal Medicine.
[28] T. MacDonald,et al. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. , 1999, British journal of clinical pharmacology.
[29] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[30] M. Safar,et al. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. , 1998, Hypertension.
[31] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[32] C. Goodman. Association for the Advancement of Medical Instrumentation , 1988 .
[33] S. Franklin,et al. Experience with the Use of an Aldosterone Antagonist in Selected Hypertensive Patients , 1972, Angiology.